ArchPoint Investors’s Gilead Sciences GILD Stock Holding History

ArchPoint Investors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-7,590	Closed	-$584K	–	116
2020 Q2	$584K	Buy	7,590 +2,025	+36%	+$155K	0.19%	59
2020 Q1	$416K	Sell	5,565 -1,460	-21%	-$101K	0.16%	63
2019 Q4	$456K	Hold	7,025	–	–	0.14%	74
2019 Q3	$445K	Buy	7,025 +3,895	+124%	+$255K	0.15%	63
2019 Q2	$211K	Buy	+3,130	New	+$206K	0.07%	81
2017 Q1	–	Sell	-4,220	Closed	-$302K	–	143
2016 Q4	$302K	Sell	4,220 -15,780	-79%	-$1.17M	0.18%	73
2016 Q3	$1.58M	Hold	20,000	–	–	0.9%	27
2016 Q2	$1.67M	Buy	+20,000	New	+$1.77M	0.95%	26

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ArchPoint Investors's GILD Position: Q3 2020 in Review

ArchPoint Investors sold out of Gilead Sciences (GILD) in Q3 2020, closing a stake of 7,590 shares — an estimated $584K sold.

ArchPoint Investors first reported a position in GILD in Q2 2016 and held it in 8 quarters. The position peaked at $1.67M in Q2 2016. 1,539 funds tracked by Wall St. Rank hold GILD as of Q3 2020.

ArchPoint Investors reported no remaining Gilead Sciences position as of Q3 2020 after selling out during the quarter.
ArchPoint Investors sold 7,590 Gilead Sciences shares in Q3 2020, an estimated $584K.
ArchPoint Investors first reported a position in Gilead Sciences in Q2 2016 and held it in 8 quarters.
ArchPoint Investors's Gilead Sciences position peaked at $1.67M in Q2 2016.
1,539 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2020.

Based on ArchPoint Investors's 13F filing for Q3 2020, filed 13 Nov 2020.